Merck: buys Acceleron for $11.5bn
(CercleFinance.com) - US drugmaker Merck said on Thursday that it has reached a definitive agreement to buy Acceleron Pharma for about 11.
5 billion dollars.
Under the terms of the deal, the healthcare giant will offer 180 dollars per share in cash to shareholders of the Nasdaq-listed biopharmaceutical company.
Acceleron specialises in developing products for the treatment of severe and rare diseases, based on the biology of the TGF-beta family and protein engineering.
Its technology has enabled it to develop novel compounds that tap into the body's ability to regulate cell growth and repair.
Its most advanced project, sotatercept, is currently in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH).
Copyright (c) 2021 CercleFinance.com. All rights reserved.
5 billion dollars.
Under the terms of the deal, the healthcare giant will offer 180 dollars per share in cash to shareholders of the Nasdaq-listed biopharmaceutical company.
Acceleron specialises in developing products for the treatment of severe and rare diseases, based on the biology of the TGF-beta family and protein engineering.
Its technology has enabled it to develop novel compounds that tap into the body's ability to regulate cell growth and repair.
Its most advanced project, sotatercept, is currently in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH).
Copyright (c) 2021 CercleFinance.com. All rights reserved.